Source article: Ngo Cheung, “DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs,” Frontiers in Psychiatry 17:1751605, 2026. https://doi.org/10.3389/fpsyt.2026.1751605
Key background reading: Ketamine’s rapid antidepressant effects have been linked to glutamate signaling, AMPA receptor activation, BDNF, mTOR, and new synaptic growth.[1–6] The prescription drug Auvelity combines dextromethorphan and bupropion and is already used for major depressive disorder.[7,15]
For decades, depression treatment has often been explained through the “chemical imbalance” story: serotonin, dopamine, norepinephrine, and so on. That story is not useless, but it is incomplete. Many people know the frustrating reality: a standard antidepressant may take four to six weeks to work, and sometimes it barely works at all.
Ketamine changed the conversation. In some patients with severe depression, ketamine can lift mood within hours or days, not weeks.[2] That is a big deal. It suggests that depression is not only about “low serotonin.” It may also involve damaged or underactive brain circuits that can sometimes be restarted quickly.
The paper discussed here proposes a bold but still unproven idea: could a fully oral combination of existing substances push the brain in a ketamine-like direction, without using IV ketamine?
The proposed combination includes:
This is not a proven treatment plan. It is a scientific hypothesis. The important question is not “Does this sound clever?” but “Will it actually work safely in controlled studies?”
To understand the idea, imagine the brain as a busy city.
Some roads are too quiet. Some traffic lights are stuck. Some neighborhoods have lost connections after years of stress. Depression, in this metaphor, is not simply a shortage of fuel. It may also be a traffic-system problem.
Two important “traffic signals” in this system are:
Ketamine appears to temporarily block certain NMDA receptors, especially on inhibitory brain cells — the “brakes.” When those brakes are briefly released, glutamate signaling increases. That glutamate then stimulates AMPA receptors, which may trigger repair pathways involving BDNF and mTOR.[1,4–6]
In plain language: ketamine may not simply “numb” the brain. It may briefly shake the system awake, allowing brain circuits to reconnect.
That reconnection matters. Chronic stress and depression have been associated with loss of synaptic connections — the tiny contact points where brain cells communicate.[1,6] Ketamine’s rapid effect may come from helping those connections regrow or work better.
Auvelity is a prescription antidepressant containing dextromethorphan and bupropion.[7,15]
Dextromethorphan affects NMDA receptors, somewhat overlapping with one part of ketamine’s mechanism. But DXM is normally broken down quickly by a liver enzyme called CYP2D6. Bupropion slows that enzyme, allowing DXM to stay active longer.
A simple analogy: DXM is the message; CYP2D6 is the shredder; bupropion slows the shredder.
The article argues that Auvelity may provide the first “spark” of ketamine-like action — NMDA modulation — but may not fully deliver the later “flame,” meaning stronger AMPA-driven plasticity. That is still a hypothesis, not a settled fact.
Clinical studies show that dextromethorphan-bupropion can help major depressive disorder, but it is not the same thing as ketamine, and it should not be treated as interchangeable with ketamine.[7,15]
The proposed regimen replaces bupropion’s CYP2D6-blocking role with other antidepressants that also inhibit CYP2D6.
Examples include:
The logic is straightforward: if DXM disappears too quickly, it may not have enough time to affect brain signaling. A CYP2D6 inhibitor can extend its presence.
But this is also where risk enters the room.
CYP2D6 does not metabolize only DXM. It helps process many medicines, including some beta-blockers, opioids, antipsychotics, and other antidepressants. Blocking it can raise drug levels unexpectedly.[8–14] For some people, that could mean side effects. For others, it could be dangerous.
There is also a genetic issue. Some people naturally have low CYP2D6 activity; others break down CYP2D6 drugs very quickly. So the same dose can behave very differently from one person to another.[14]
This is why the idea cannot responsibly be reduced to “just combine these pills.” Biology is messier than that.
The next proposed piece is piracetam.
In the article’s model, DXM helps create the “spark,” while piracetam might help AMPA receptors respond more strongly. If NMDA receptors are like gates and AMPA receptors are like fast signal doors, piracetam is imagined as something that helps those doors open more easily.
Some older research suggests piracetam may influence AMPA receptor density or synaptic plasticity, especially in animal or aging-brain studies.[16–18] But the evidence for piracetam as an antidepressant enhancer in humans is far from conclusive.
A good way to say it is this: piracetam is an interesting candidate, not a proven answer.
This distinction matters. The article’s proposal is mechanistically neat, but medicine is full of neat ideas that did not survive proper testing.
The final proposed ingredient is L-glutamine.
Glutamine is an amino acid involved in the glutamate–glutamine cycle. In the brain, it helps maintain supplies for glutamate signaling. If glutamate is the “working currency” of fast excitatory communication, glutamine is part of the supply chain.
Think of a restaurant kitchen. DXM changes how the stove works. Piracetam may make the serving window more responsive. But if the pantry is empty, nothing much happens. Glutamine is proposed as a way to help refill the pantry.
Animal studies suggest glutamine supplementation may reverse some chronic-stress-related changes in glutamate/glutamine levels and produce antidepressant-like effects.[19,20] Other studies suggest glutamine may also help regulate excessive glutamate activity under inflammatory conditions.[22–24]
However, translating this into human depression treatment is not simple. The brain is not a smoothie recipe. More “precursor” does not automatically mean better mood, and too much excitatory signaling can be harmful.
The article includes a major safety discussion, and for good reason.
Combining DXM with antidepressants that raise serotonin or inhibit CYP2D6 can increase the risk of:
Serotonin toxicity is especially important. DXM has serotonergic properties, and when its levels rise because CYP2D6 is blocked, the risk may increase.
This proposed regimen would be especially concerning for people with:
The article describes early naturalistic clinical experience, but that is not the same as a randomized controlled trial. Case series can generate useful clues, but they can also overestimate benefit and underestimate harm.
So the most responsible takeaway is: this idea deserves careful study, not casual self-experimentation.
One useful feature of the proposal is that it makes testable predictions.
If the theory is right, researchers should eventually be able to show that the combination:
If those things do not happen, the theory would need to be revised or abandoned.
That is how good science should work. A hypothesis is not a victory lap. It is an invitation to test.
This paper presents an ambitious idea: using existing oral agents to imitate more of ketamine’s rapid antidepressant pathway. The concept is built around a chain reaction: keep DXM active, reduce NMDA-related “static,” encourage AMPA signaling, and support glutamate cycling.
It is an intriguing model. It is also not yet proven.
For lay readers, the easiest summary is this:
Ketamine may work quickly because it helps stuck brain circuits reconnect. This proposed oral strategy tries to imitate parts of that process using already-known substances. But the combination has not yet been proven safe and effective in rigorous trials, and it should not be attempted without specialist medical supervision.
The idea is worth studying. It is not ready to be treated as established care.
We wish to inform the r/science community of an article submitted to the subreddit that has since been retracted by the journal. The submission garnered broad exposure on r/science and significant social media coverage. Per our rules, the flair on this submission has been updated with "RETRACTED". The submission has also been added to our wiki of retracted submissions.
--
The article "Longitudinal Data From the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not" has been retracted from JACC: Advances as of March 11, 2026. Numerous concerns were raised shortly after publication, including a Letter to the Editor in May 2025 that highlighted "selective reporting" of data, questionable statistical analysis, and too short a timeframe for the study. An Expression of Concern was eventually issued by the Editors in January 2026 to report that the study was undergoing further review.
The article was ultimately retracted at the request of the authors and the Editors. The methodological concerns were judged to have impacted the reliability of the data and were too great to be corrected with a corrigendum. Several authors have recently submitted a preprint reporting a re-analysis of the data that allegedly addresses the various concerns.
--
Should you encounter a submission on r/science that has been retracted, please notify the moderators via Modmail.